ABSTRACT
Stroke is a neurological disease which is difficult to conquer clinically .Cell transplantation based on mesenchymal stem cells(MSCs) provides hope for the healthy recovery of stroke patients , but our study of MSCs for stroke therapy is not thorough enough and still faces some problems .The aim of this paper is to summarize the problems with MSCs in the treatment of stroke from the perspectives of tissue source , preparation process, time window, transplantation pathway , pretreatment , combined medication and tracer method , in order to provide guidance for scientific research and clinical application.
ABSTRACT
We cloned and prokaryoticly expressed the gene encoding Redox regulator(Rex)of Streptococcus suis serotype 2 and analyzed biological information and in vitro binding activity.The encoding Rex gene of SS2-1 strain was amplified by PCR with the designed primers,and then cloned into prokaryotic expression plasmid pET28a.The recombinant plasmid pET28a-Rex was transformed into E.coli BL21.After induced expression by IPTG,the Rex protein was obtained.The binding activity of Rex protein and DNA was analyzed by gel mobility shift assay (EMSA) in vitro.Purification of recombinant protein Rex was successfully expressed.The presence of NAD+ did not have major effect on mobility shift,but addition of NADH almost abolished such a binding activity.By in vitro binding assay,Rex was found to regulate the expression of Prex in response to NADH/NAD+ equilibrium.